After months of suspense, two pharmaceutical industry trade groups have agreed to drop a lawsuit against the state of Nevada over a new law that requires drug makers to report a wide array of pricing information about their diabetes medicines.
The move comes just weeks after state officials modified a regulation to allow companies to mark certain pricing data as confidential when they begin complying with the new transparency law, according to court documents.
About the Author Reprints
